Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Annette Hasenburg Prof., Dr, med
Annette Hasenburg Prof., Dr, med Advisory Board
Sara Tolaney MD, MPH
Sara M. Tolaney MD, MPH Advisory Board
Roxana Dronca MD
Roxana S. Dronca MD Advisory Board
See All Experts
featured
Published in Oncology

Journal Scan / Research · May 19, 2016

Bevacizumab Plus FOLFIRI and Bevacizumab Plus mFOLFOX6 as First-Line Treatment in Metastatic Colorectal Cancer

Annals of Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Annals of Oncology
Randomized Phase III Study of Bevacizumab Plus FOLFIRI and Bevacizumab Plus mFOLFOX6 as First-Line Treatment for Patients With Metastatic Colorectal Cancer (WJOG4407G)
Ann. Oncol 2016 May 13;[EPub Ahead of Print], K Yamazaki, M Nagase, H Tamagawa, S Ueda, T Tamura, K Murata, T Eguchi Nakajima, E Baba, M Tsuda, T Moriwaki, T Esaki, Y Tsuji, K Muro, K Taira, T Denda, S Funai, K Shinozaki, H Yamashita, N Sugimoto, T Okuno, T Nishina, M Umeki, T Kurimoto, T Takayama, A Tsuji, M Yoshida, A Hosokawa, Y Shibata, K Suyama, M Okabe, K Suzuki, N Seki, K Kawakami, M Sato, K Fujikawa, T Hirashima, T Shimura, K Taku, T Otsuji, F Tamura, E Shinozaki, K Nakashima, H Hara, T Tsushima, M Ando, S Morita, N Boku, I Hyodo

Further Reading

Most Read This Week

Recently Updated